Loading... (0%)
About liver disease

GENFIT: A COMPREHENSIVE APPROACH TO NASH

NIS4: Our blood-based diagnostic test for the identification of patients with NASH...
LEARN MORE
Health prevention, medical education, dissemination of information related to NASH...
ACCESS WEBSITE

COMPANY LIFE

We are a late-stage biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

Update on Corporate Governance

Joint interview: Jean-François Mouney, Co-founder, CEO, Chairman of the Board; Pascal Prigent, Future CEO; Dean Hum, Chief Operating Officer & Chief Scientific Officer

 

Read “Update on Corporate Governance”

Press releases
  • GENFIT: Dr. Carol L. Addy Joins as Chief Medical Officer
    09/09/2019
  • GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
    09/02/2019
  • FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
    07/29/2019
  • GENFIT: Half-Year report of Liquidity Contract with Crédit Industriel et Commercial
    07/09/2019
  • GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
    06/24/2019
Events
libero. ipsum eleifend tempus commodo justo nunc Donec efficitur. Sed risus ut